SOAT1 and Alzheimer disease: Over the last decade, the marked advances that have been made in understanding the impact of JAK/STAT signaling pathway on the pathogenesis of AD encouraged the use of JAK inhibitors as a therapeutic alternative for this disease [10,11,16].